Research location
New Hyde Park
New York, United States
Research activity in New Hyde Park
New York, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 380 trials and 388 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in New Hyde Park
380 linked trials · page 1 of 8AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)NCT07611110 · 2026-05-04 · 1 site observation
RECRUITING
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid TumorsNCT07287995 · 2026-02-05 · 1 site observation
RECRUITING
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid TumorsNCT07277270 · 2025-12-03 · 1 site observation
RECRUITING
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)NCT07103018 · 2025-11-21 · 1 site observation
RECRUITING
Starting Early to Prevent Obesity Using Telehealth (StEP OUT): Pilot RCTNCT07254065 · 2025-11-14 · 1 site observation
RECRUITING
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsNCT06997029 · 2025-08-01 · 1 site observation
RECRUITING
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA TreatmentNCT06750289 · 2025-03-28 · 1 site observation
RECRUITING
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)NCT06388421 · 2025-01-23 · 1 site observation
RECRUITING
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint InhibitorNCT06472245 · 2024-12-03 · 2 site observations
RECRUITING
A Study of Lower Radiotherapy Dose to Treat Children With CNS GerminomaNCT06368817 · 2024-10-22 · 1 site observation
RECRUITING
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)NCT06452277 · 2024-08-28 · 1 site observation
RECRUITING
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerNCT06380751 · 2024-08-01 · 1 site observation
RECRUITING
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLCNCT06216301 · 2024-07-31 · 1 site observation
RECRUITING
Maturation of Arteriovenous Fistula With Automated Sonography Assessments TrialNCT06190717 · 2024-02-21 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLCNCT06010329 · 2023-12-27 · 1 site observation
RECRUITING
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenTNCT06059638 · 2023-12-27 · 1 site observation
RECRUITING
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.NCT06072612 · 2023-12-05 · 1 site observation
RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)NCT06126224 · 2023-08-28 · 1 site observation
RECRUITING
Ladarixin With Sotorasib in Advanced NSCLCNCT05815173 · 2023-08-01 · 1 site observation
RECRUITING
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation
RECRUITING
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaNCT05235165 · 2022-04-01 · 1 site observation
RECRUITING
A Study of Sigvotatug Vedotin in Advanced Solid TumorsNCT04389632 · 2020-06-08 · 1 site observation
RECRUITING
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer TreatmentNCT01790152 · 2014-03-05 · 1 site observation
RECRUITING
Advancing Ethical Goals In Society TrialNCT07824245 · 2027-03-01 · 1 site observation
NOT_YET_RECRUITING
SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients With Type 1 and Type 2 DiabetesNCT06719531 · 2025-05-01 · 1 site observation
WITHDRAWN
A BCT Intervention for an Hourly Activity Habit Among Caregivers for Persons With AD/ADRDNCT06801912 · 2025-03-25 · 1 site observation
COMPLETED
BCT Intervention For Walking Habit Among Caregivers of People With AD/ADRDNCT06803797 · 2025-03-18 · 1 site observation
COMPLETED
Starting Early to Prevent Obesity Using Telehealth (StEP OUT): Intervention Development TrialNCT06486922 · 2024-06-10 · 1 site observation
COMPLETED
Virtual Personalized Exercise Program for Lung Cancer PatientsNCT06540495 · 2024-06-03 · 1 site observation
UNKNOWN
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe AsthmaNCT06376045 · 2024-05-24 · 1 site observation
TERMINATED
Rectal Spacers in Prostate Cancer Patients Undergoing Radiation TherapyNCT06599476 · 2024-05-21 · 1 site observation
ACTIVE_NOT_RECRUITING
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · 2024-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Ladarixin With Sotorasib in Advanced NSCLC - Phase IINCT05815186 · 2024-04-01 · 1 site observation
WITHDRAWN
Reduce Loneliness in Care Partners of Persons With AD/ADRDNCT05460494 · 2024-03-06 · 1 site observation
COMPLETED
SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)NCT06140303 · 2024-02-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant HypertensionNCT06153693 · 2023-11-22 · 1 site observation
COMPLETED
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsNCT06120491 · 2023-11-21 · 1 site observation
ACTIVE_NOT_RECRUITING
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Eatable Alphabet as a Nutrition Education ToolNCT05166629 · 2023-09-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaNCT05851443 · 2023-07-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGMNCT05714059 · 2023-02-28 · 1 site observation
COMPLETED
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)NCT05555732 · 2023-01-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C MutationNCT05609578 · 2022-11-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Open-label Extension for Phase 3 Clinical Trials of SimufilamNCT05575076 · 2022-11-07 · 1 site observation
TERMINATED
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382286 · 2022-07-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382299 · 2022-07-20 · 1 site observation
ACTIVE_NOT_RECRUITING
The AUDACITY Study (AllUrion Device in Adults With Clinical ObesITY)NCT05368259 · 2022-05-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Integrated Intervention for Breast Cancer Survivors With DiabetesNCT05092477 · 2022-01-27 · 1 site observation
COMPLETED
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid MalignanciesNCT05199272 · 2021-12-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung CancerNCT05014815 · 2021-11-16 · 1 site observation
COMPLETED
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.